# Sanifit Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sanifit-therapeutics-s-a

- Industry: Pharmaceuticals
- Headquarters: Palma, Spain
- Website: www.sanifit.com
- Total disclosed funding: $109M
- Latest round: Series D (Jun 26, 2019)
- Investors on record: 15

## About

Based in Palma de Mallorca, Spain, and founded in 2007 by Joan Perello, Laboratoris Sanifit, S.L. is a clinical-stage biopharmaceutical company that treats vascular calcification disorders. In June 2019, Laboratoris Sanifit, S.L. raised EUR 17 million in venture debt financing from unspecified investors. The company has raised a total of USD 128.31 million in funding and Joan Perello is the CEO.

Sanifit Therapeutics, S.A. is developing SNF472, which is a small molecule that is a selective and potent inhibitor of hydroxyapatite (HAP) crystallization that treats calciphylaxis or CUA (calcific uremic arteriolopathy) for patients undergoing dialysis. As of December 2021, SNF472 is under phase 3 clinical development.

Sanifit Therapeutics, S.A. has generated USD 0.002 million in revenue in the fiscal year ended in December 2019.

## Funding rounds

- Series D, Jun 26, 2019, $63M — Andera Partners, Gilde Healthcare, Forbion, Riva y Garcia Private Equity, Ysios Capital Partners, Lundbeckfond Ventures, Caixa Capital Risc, Columbus Venture Partners, Naos SAS, Alta Life Sciences
- Series C, Sep 8, 2015, $41M — Gilde Healthcare, Forbion, Ysios Capital Partners, La Caixa Group, Lundbeckfond Ventures, Edmond de Rothschild Asset Management, Baxter Ventures
- Series B, Aug 1, 2014, $4.8M — Riva y Garcia Private Equity, Caixa Capital Risc, Nefrona Foundation, Somtobir

## Investors

- Riva y Garcia Private Equity (https://capitalatlas.ai/funds/riva-y-garcia-private-equity) — Series B, Series D
- Caixa Capital Risc — Series B, Series D
- Nefrona Foundation — Series B
- Somtobir — Series B
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series C, Series D
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C, Series D
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series C, Series D
- La Caixa Group — Series C
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series C, Series D
- Edmond de Rothschild Asset Management (https://capitalatlas.ai/funds/edmond-de-rothschild-asset-management) — Series C
- Baxter Ventures (https://capitalatlas.ai/funds/baxter-ventures) — Series C
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series D
- Columbus Venture Partners (https://capitalatlas.ai/funds/columbus-venture-partners) — Series D
- Naos SAS — Series D
- Alta Life Sciences — Series D